Thursday, August 15, 2024

Candidate Malaria Vaccine Provides Lasting Protection in NIH-Sponsored Trials

NIH/NIAID Template Banner

 

Thursday, August 15, 2024

Candidate Malaria Vaccine Provides Lasting Protection in NIH-Sponsored Trials

malaria images montage

A candidate malaria vaccine administered to Malian women prior to pregnancy was safe and provided substantial protection against infection that was sustained over the course of two malaria seasons without the need for a booster dose. Malaria during pregnancy is estimated to cause up to 50,000 maternal deaths and 200,00 stillbirths annually. If confirmed through additional clinical trials, the approach modeled in this NIAID-sponsored study could lead to improved ways to prevent malaria in this vulnerable population. The results were published in Lancet Infectious Diseases.

Learn More Button


This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107 GovDelivery logo

No comments:

Post a Comment

You ➕ this quiz 🟰 A certified genius

        Happy Friday! I think by now you've gathered that Fridays are for trivia, right? Of course you did because you're smart...